Ikarian Capital, LLC Prothena Corp Public LTD CO Transaction History

Ikarian Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$21.63 - $57.65 $9.46 Million - $25.2 Million	-437,430 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$11.0 - $28.24 $8.24 Million - $21.2 Million	-749,270 Reduced 63.14%	437,430 $11 Million
Q4 2020 Feb 12, 2021	BUY	$10.12 - $13.94 $12 Million - $16.5 Million	1,186,700 New	1,186,700 $14.3 Million
Q1 2020 May 15, 2020	SELL	$7.54 - $15.77 $224,933 - $470,450	-29,832 Closed	0 $0
Q4 2019 Jan 31, 2020	BUY	$7.48 - $17.01 $223,143 - $507,442	29,832 New	29,832 $472,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $561M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.